Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019

Evan M. Bloch, Daniele Focosi, Shmuel Shoham, Jonathon Senefeld, Aaron A.R. Tobian, Lindsey R. Baden, Pierre Tiberghien, David J. Sullivan, Claudia Cohn, Veronica Dioverti, Jeffrey P. Henderson, Cynthia So-Osman, Justin E. Juskewitch, Raymund R. Razonable, Massimo Franchini, Ruchika Goel, Brenda J. Grossman, Arturo Casadevall, Michael J. Joyner, Robin K. AveryLiise Anne Pirofski, Kelly A. Gebo

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-Titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.

Original languageEnglish (US)
Pages (from-to)2018-2024
Number of pages7
JournalClinical Infectious Diseases
Issue number11
StatePublished - Jun 1 2023

Bibliographical note

Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.


  • antibodies
  • immunocompromised host
  • passive immunization
  • plasma

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't


Dive into the research topics of 'Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019'. Together they form a unique fingerprint.

Cite this